CASP3 and prostate carcinoma: It also inhibits the level of cyclin D1, survivin, VEGF, Bcl-2, eNOS, iNOS, and MMPs and elevates the level of caspases-3, caspases-7, PARP, p53, p21, and Bax in prostate carcinoma and lung cancer [104,105].